|
RNF19A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.25000000001019E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.89400000000828E-05 |
| Normal-vs-Stage2 |
1.25050000021609E-07 |
| Normal-vs-Stage3 |
1.66000000001443E-06 |
| Normal-vs-Stage4 |
1.55330999999093E-05 |
| Stage1-vs-Stage2 |
8.323800E-03 |
| Stage1-vs-Stage3 |
4.207600E-02 |
| Stage1-vs-Stage4 |
5.458000E-02 |
| Stage2-vs-Stage3 |
3.126000E-01 |
| Stage2-vs-Stage4 |
5.986000E-01 |
| Stage3-vs-Stage4 |
7.615600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.55534999999318E-05 |
| Normal-vs-AfricanAmerican |
3.540500E-03 |
| Normal-vs-Asian |
3.169700E-04 |
| Caucasian-vs-AfricanAmerican |
4.738200E-01 |
| Caucasian-vs-Asian |
7.274200E-01 |
| AfricanAmerican-vs-Asian |
6.851000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.99129999995029E-06 |
| Normal-vs-Female |
1.50254999999877E-05 |
| Male-vs-Female |
5.486000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.624700E-04 |
| Normal-vs-Age(41-60Yrs) |
7.13289999954014E-07 |
| Normal-vs-Age(61-80Yrs) |
2.97679999983202E-07 |
| Normal-vs-Age(81-100Yrs) |
1.347180E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.457400E-03 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.823200E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.302200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.903200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.132800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.397800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.499500E-02 |
| Classical-VS-Follicular |
4.622600E-03 |
| Classical-VS-Other |
5.292000E-01 |
| Classical-VS-Normal |
1.423050E-04 |
| Tall-VS-Follicular |
8.501800E-01 |
| Tall-VS-Other |
7.082600E-01 |
| Tall-VS-Normal |
1.9699699999931E-05 |
| Follicular-VS-Other |
7.542600E-01 |
| Follicular-VS-Normal |
5.1234999998151E-07 |
| Other-VS-Normal |
4.820400E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.89189999999506E-07 |
| Normal-vs-N1 |
7.70960000000542E-05 |
| N0-vs-N1 |
4.065600E-01 |
|
|
